semaglutide essence ESSENCE: in Patients with Metabolic Dysfunction–Associated Steatohepatitis Novo Nordisk Announces Positive Results

Semaglutide-associated hyposalivation: A report of case series

With its patent expiration, the advent of generic Semaglutide offers new possibilities, opening up a more affordable avenue for millions

At 208 weeks, semaglutide was associated with mean reduction in weight (10.2%), waist circumference (7.7 cm) and waist-to-height ratio (6.9%) versus placebo (1.5%, 1.3 cm and 1.0%, respectively

Absolute contraindications: Active malignancy IGF-1 is mitogenic and promotes cell growth Pregnancy Disruption of the hypothalamic-pituitary axis by injury, tumor, or surgery Hypersensitivity to tesamorelin or mannitol (an excipient in the formulation) A qualified metabolic provider will screen for all of these before initiating therapy

doi:10.3389/fpubh.2022.818816